Insider Selling: NIOX Group (LON:NIOX) Insider Sells 193,361 Shares of Company Stock

Key Points

• NIOX Group insider Ian Johnson sold 193,361 shares on November 2 at an average price of 80 pence, for total proceeds of £154,688.80.
• The shares later traded at 64.20 pence, down 0.20 pence on the day; the company’s market capitalization was approximately £270.2 million.
• NIOX reported quarterly earnings of 1.41 pence per share, with a 14.74% net margin and 10.01% return on equity.

NIOX Group Plc (LON:NIOX - Get Free Report) insider Ian Johnson sold 193,361 shares of the company's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of GBX 80, for a total transaction of £154,688.80.

NIOX Group Price Performance

NIOX traded down GBX 0.20 during trading on Wednesday, reaching GBX 64.20. 720,624 shares of the stock were exchanged, compared to its average volume of 904,284. The company has a debt-to-equity ratio of 1.06, a current ratio of 4.60 and a quick ratio of 1.94. The company has a market capitalization of £270.20 million, a price-to-earnings ratio of 39.39 and a beta of 0.92. NIOX Group Plc has a 1 year low of GBX 53.84 and a 1 year high of GBX 80. The business's 50 day moving average price is GBX 67.34 and its two-hundred day moving average price is GBX 63.13.

NIOX Group (LON:NIOX - Get Free Report) last issued its quarterly earnings data on Wednesday, September 30th. The company reported GBX 1.41 EPS for the quarter. NIOX Group had a net margin of 14.74% and a return on equity of 10.01%. As a group, equities research analysts anticipate that NIOX Group Plc will post 1.17 earnings per share for the current year.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.